Professional Documents
Culture Documents
Targets For Development of Anti-Ulcer Agents
Targets For Development of Anti-Ulcer Agents
By
Vamsi rajasekhara reddy
CONTENT
FACTORS FOR ULCERATION PHYSIOLOGY OF ACID SECRETION TARGETS OF ANTIULCER AGENTS MECHANISM OF ACTION SIDE EFFECTS
Gastric acid secreted by parietal cells. Basolateral membrane of these cells contain 3 main stimulants Gastrin (from G cells) Histamine (from enterochromaffin cells) Acetylcholine (from vagal efferent) These stimulants stimulate proton pump Stimulated proton pump translocates from cytoplasmic vesicles to the secretory canaliculus of the parietal cells + Uses energy derived from hydrolysis of ATP, to transport H out of parietal + cells in exchange for K Hydrogen ions combine with Chloride ions to form hydrochloric acid(HCl) Hydrochloric acid is secreted in to gastric lumen.
TARGETS
H2 receptor eg: Cimetidine, Ranitidine, Famotidine Proton Pump eg: Omeprazole, Lansoprazole, Pantoprazole M1 receptor eg: Pirenzipine, propantheline, Oxyphenonium Gastrin receptors eg:Misoprostol, Enprostil, Rioprostil Cell wall eg:sucralfate Stomach eg: Antacids ( sodium bicarbonate, Magnesium hydroxide ) Helicobacter pylori eg:Amoxycillin, Clarithromycin, Metronidazole
H2 RECEPTOR
ranitidine
cimetidine
SAR
Imidazole ring exist in two tautomeric forms. In these form I to be necessary for maximal H2 antagonist activity. When R is substituted with methyl group, the activity is potentiated The other heterocyclics like furan, thiazole enhance the potency and selectivity of H2 receptor antagonism
The ring and terminal nitrogen should be separated by four carbon atom for optimum activity. The shorter chain decrease the activity. The side chain should contain an electron with drawing substituents and an Isosteric thioether (- S-) link in place of methylene group (- CH2) leads to more active compound. The terminal nitrogen should be polar, non basic substituents for maximal activity.
Synthesis of Cimetidine
PROTON PUMP
Examples
HOH2C
N SOCl2
ClH2C
H3C OCH3
CH3
H3C
CH3 NaOH
KS
N NH2
S H3CO
SH
H3CO
NH2
N H potassium ethyl H5C2O xanthate 5 methoxy 2 mercaptobenzimidazole O N OH H3CO Cl O N NH S CH2 CH3 OCH3 N CH3 N H S H3C OCH3 CH2 N CH3
H3CO
Omeprazole
cell
Activated in canaliculi & binds covalently to extracellular
domain of H+ K+ ATPase
coated tablets
Pantoprazole also given intravenously Half life 1.5 hrs Since it requires acid for activation - given 1 hr
tumor in rats
But no evidence of such tumors in man Inhibit CYP 450 & hence metabolsim of warfarin,
phenytoin, etc
Pantoprazole & Rabeprazole have no significant
interactions
M1 RECEPTORS
Cl O
+
N 3 Amino
-
NH
-H C l
O 2N
Cl
Chloropyridine H2 Raney Ni
H N
Cl O
2 0 0 C
NH N H
-H C l
O H 2N
2 Cl
ClCOCH
N(CH 3 ) 3 H N HN N CH3
H N
N O O
N O ClH 2 C O
-HCl
N H 3C
M1 RECEPTOR ANTAGONIST
Block M1 receptor at enterochromaffin cells Donot cross Blood Brain Barrier Nonselective Blurred vision, dry mouth, urinary retention Delay gastric emptying Eg: Propantheline, Oxyphenonium, Pirenzepine, Telenzepine
GASTRIN RECEPTORS
PROSTAGLANDIN ANALOGUES
Produced in gastric mucosa Inhibits gastrin release Enhances mucosal blood flow Stimulates secretion of mucus and bicarbonates NSAID associated gastrointestinal injury Need multiple daily dosing Diarrhoea, abdominal cramps, uterine contractions Eg: Misoprostol, Enprostil Rioprostil
CELL WALL
Sucralfate
hydroxide
Concurrent antacids, H2 antagonist avoided
Available compounds :
Bismuth subsalicylate in USA Bismuth subcitrate in Europe Bismuth dinitrate
STOMACH
ANTACIDS
Duration of action :
30 min when taken in empty stomach 2 hrs when taken after a meal
Side effects :
Al3+ antacids constipation (As they relax gastric
Antacid Interactions
Adsorb drugs and form insoluble complexes that are not absorbed
HELICOBACTER PYLORI
Eradication of H.pylori
Triple Therapy The BEST among all the Triple therapy regimen is Omeprazole / Lansoprazole Clarithromycin Amoxycillin / Metronidazole - 20 / 30 mg - 500 mg - 1gm / 500 mg
Given for 14 days followed by P.P.I for 4 6 weeks Short regimens for 7 10 days not very effective
Bismuth subsalicylate
Metronidazole Tetracycline
Tetracycline
Quadruple Therapy
Given when Triple Therapy fails Omeprazole / Lansoprazole - 20 / 30
FUTURE PROSPECTS
Reversible proton pump inhibitors are currently underdevelopment by the company Astra-Zeneca. Development of vaccine for Helicobacter pylori is currently being explored.
REFERENCE:
FOYES PRINCIPLES OF MEDICINAL CHEMISTRY 1019-1024 Essentials of MEDICAL PHARMACOLOGY K D Tripathi 587-598 Clinical Pharmacology by P N Bennett M J Brown 561-568 An Introduction to Medicinal Chemistry by Graham L. Patrick 642-670 Principles of Pharmacology by H L Sharma K K Sharma 386-399 http://aac.asm.org/cgi/content/full/48/12/4582?maxtoshow=&HITS=10 &hits=10&RESULTFORMAT=&fulltext=cimetidine+synthesis&searchid=1&FI RSTINDEX=0&resourcetype=HWCIT http://aac.asm.org/cgi/content/full/51/3/831 http://jac.oxfordjournals.org/cgii/content/full/59/1/160
THANK YOU